Lisa Walter
Stock Analyst at RBC Capital
(2.58)
# 2,225
Out of 5,129 analysts
10
Total ratings
66.67%
Success rate
13.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $7.46 | +114.48% | 1 | Nov 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $26 → $32 | $9.25 | +245.95% | 2 | Nov 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $41 → $45 | $30.07 | +49.65% | 2 | Nov 6, 2025 | |
| EYPT EyePoint | Maintains: Outperform | $28 → $39 | $12.85 | +203.50% | 2 | Nov 6, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $569 → $587 | $475.85 | +23.36% | 2 | Oct 30, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $17 → $19 | $22.29 | -14.76% | 1 | Aug 1, 2025 |
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $7.46
Upside: +114.48%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $9.25
Upside: +245.95%
Viridian Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $41 → $45
Current: $30.07
Upside: +49.65%
EyePoint
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $12.85
Upside: +203.50%
United Therapeutics
Oct 30, 2025
Maintains: Outperform
Price Target: $569 → $587
Current: $475.85
Upside: +23.36%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Sector Perform
Price Target: $17 → $19
Current: $22.29
Upside: -14.76%